<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158246</url>
  </required_header>
  <id_info>
    <org_study_id>Cttq-POWER</org_study_id>
    <nct_id>NCT03158246</nct_id>
  </id_info>
  <brief_title>Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women</brief_title>
  <official_title>Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cttq</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy and safety of generic zoledronic acid (Yigu®) and original
      zoledronic acid (Aclasta®) in the treatment of postmenopausal osteoporotic women in China.
      Four hundred and sixty-six subjects will be randomised (1:1ratio) to either Yigu® 5mg IV or
      Aclasta® 5mg IV treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone
      density at 12 months in postmenopausal women with osteoporosis, and it significantly reduced
      the risk of vertebral fractures additionally.

      In this research, the efficacy and safety of generic zoledronic acid injection in the
      treatment of postmenopausal osteoporosis will be evaluated, using original drug as control
      drug. It will provide evidence for reasonable clinical administrations.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">March 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BMD T-scores</measure>
    <time_frame>12 months</time_frame>
    <description>BMD T-scores (spine, hip and femoral neck) are determined versus baseline at the visits time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BMD T-scores</measure>
    <time_frame>6 months</time_frame>
    <description>BMD T-scores (spine, hip and femoral neck) are determined versus baseline at the visits time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemical markers of bone turnover</measure>
    <time_frame>14 days, 6 months and 12 months</time_frame>
    <description>Biochemical markers of bone turnover are determined versus baseline at the visits time. Including β-CTX and P1NP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractures</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of fracture of all parts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">466</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Yigu Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)
600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclasta Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)
600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic Zoledronic Acid</intervention_name>
    <description>Generic Zoledronic Acid (Yigu®) 5mg/100ml injection</description>
    <arm_group_label>Yigu Group</arm_group_label>
    <other_name>Yigu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Original Zoledronic Acid</intervention_name>
    <description>Original Zoledronic Acid (Aclasta®) 5mg/100ml injection</description>
    <arm_group_label>Aclasta Group</arm_group_label>
    <other_name>Aclasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium</intervention_name>
    <description>600mg/d calcium for oral daily</description>
    <arm_group_label>Yigu Group</arm_group_label>
    <arm_group_label>Aclasta Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>925IU/d vitamin D for oral daily</description>
    <arm_group_label>Yigu Group</arm_group_label>
    <arm_group_label>Aclasta Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women between the ages of 46 and 80（cessation of menses for 12 months
             for any reason）

          -  Subjects with osteoporosis diagnosed according to the World Health Organization (WHO)
             criteria：they had a BMD T-score of −2.5 or less at the spine or femoral neck；or they
             had low bone mass，defined as BMD T-score less than -1.0 and more than -2.5 at the
             spine or femoral neck，with the history of fragility fracture(Fracture site included
             vertebra, hip,proximal humera, distal radius, distal ulna)

          -  Subjects signed informed consent voluntarily

        Exclusion Criteria:

          -  Any non-primary osteoporosis skeletal disease

          -  Subjects with abnormal hepatic function and renal function（alanine transaminase(ALT)
             and aspartate transaminase(AST) are 2 times higher than the upper limits of
             normal(ULN);plasma creatinine concentration and blood urea nitrogen are more than 1.5
             ULN or calculated creatinine clearance less than 60 ml/min）

          -  Subjects with serum calcium greater than 2.75 mmol/L (11.0 mg/dL) or less than 2.00
             mmol/L (8.0 mg/dL)

          -  Subjects with severe heart disease, blood disease, mental diseases

          -  Subjects with cancer and other serious progressive disease

          -  Prior therapy with bisphosphonates within 12 months before trial entry, prior therapy
             with parathyroid hormone 1-34 or 1-84, estrogen, selective estrogen receptor
             modulators, strontium more than 2 weeks within 6 months, prior therapy with oral or
             intravenous glucocorticoid more than 3 months within 6 months

          -  Subject is hypersensitivity to experimental drugs, comparator drugs and their
             metabolites

          -  Subjects who participated in other drugs or medical devices clinical studies as
             subjects within 3 months before this study

          -  Subjects judged unfit for this study by investigators
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Weibo</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Mei</last_name>
    <phone>+86 13671312468</phone>
    <email>limeilzh@sina.com</email>
  </overall_contact>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>May 21, 2017</last_update_submitted>
  <last_update_submitted_qc>May 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>zoledronic acid</keyword>
  <keyword>Yigu</keyword>
  <keyword>Aclasta</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>BMD</keyword>
  <keyword>fracture</keyword>
  <keyword>Biochemical markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

